Page 1648 - Williams Hematology ( PDFDrive )

1622 Part XI: Malignant Lymphoid Diseases Chapter 97: Hodgkin Lymphoma 1623

248. Travis LB, Gospodarowicz M, Curtis RE, et al: Lung cancer following chemotherapy 264. Horning SJ, Hoppe RT, Kaplan HS, et al: Female reproductive potential after treatment
and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–192, 2002. for Hodgkin’s disease. N Engl J Med 304:1377–1382, 1981.
249. De Bruin ML, Sparidans J, van’t Veer MB, et al: Breast cancer risk in female survi- 265. Anselmo AP, Cartoni C, Bellantuono P, et al: Risk of infertility in patients with Hodgkin’s
vors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 75:155–158,
27:4239–4246, 2009. 1990.
250. van Leeuwen FE, Klokman WJ, Stovall M, et al: Roles of radiation dose, chemotherapy, 266. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy
and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol
95:971–980, 2003. 21:601–605, 1985.
251. Swerdlow AJ, Schoemaker MJ, Allerton R, et al: Lung cancer after Hodgkin’s disease: A 267. Hodgson DC, Pintilie M, Gitterman L, et al: Fertility among female Hodgkin lym-
nested case-control study of the relation to treatment. J Clin Oncol 19:1610–1618, 2001. phoma survivors attempting pregnancy following ABVD chemotherapy. Hematol
252. Eriksson F, Gagliardi G, Liedberg A, et al: Long-term cardiac mortality following radia- Oncol 25:11–15, 2007.
tion therapy for Hodgkin’s disease: Analysis with the relative seriality model. Radiother 268. Behringer K, Breuer K, Reineke T, et al: Secondary amenorrhea after Hodgkin’s lym-
Oncol 55:153–162, 2000. phoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and
253. Hancock SL, Hoppe RT, Horning SJ, et al: Intercurrent death after Hodgkin disease the use of oral contraceptives during therapy: A report from the German Hodgkin’s
therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 109:183–189, 1988. Lymphoma Study Group. J Clin Oncol 23:7555–7564, 2005.
254. Boivin JF, Hutchison GB, Lubin JH, et al: Coronary artery disease mortality in patients 269. Hancock SL, Cox RS, McDougall IR: Thyroid diseases after treatment of Hodgkin’s dis-
treated for Hodgkin’s disease. Cancer 69:1241–1247, 1992. ease. N Engl J Med 325:599–605, 1991.
255. Adams MJ, Lipsitz SR, Colan SD, et al: Cardiovascular status in long-term survivors of 270. Carmel RJ, Kaplan HS: Mantle irradiation in Hodgkin’s disease. An analysis of tech-
Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139–3148, 2004. nique, tumor eradication, and complications. Cancer 37:2813–2825, 1976.
256. Heidenreich PA, Hancock SL, Lee BK, et al: Asymptomatic cardiac disease following 271. Horning SJ, Adhikari A, Rizk N, et al: Effect of treatment for Hodgkin’s disease on
mediastinal irradiation. J Am Coll Cardiol 42:743–749, 2003. pulmonary function: Results of a prospective study. J Clin Oncol 12:297–305, 1994.
257. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after 272. Smith LM, Mendenhall NP, Cicale MJ, et al: Results of a prospective study evaluating
treatment for Hodgkin lymphoma. Blood 109:1878–1886, 2007. the effects of mantle irradiation on pulmonary function. Int J Radiat Oncol Biol Phys
258. Swerdlow AJ, Higgins CD, Smith P, et al: Myocardial infarction mortality risk after 16:79–84, 1989.
treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 273. Donaldson SS, Kaplan HS: Complications of treatment of Hodgkin’s disease in chil-
99:206–214, 2007. dren. Cancer Treat Rep 66:977–989, 1982.
259. De Bruin ML, Dorresteijn LD, van’t Veer MB, et al: Increased risk of stroke and tran- 274. Rosner F, Zarrabi MH: Late infections following splenectomy in Hodgkin’s disease.
sient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst Cancer Invest 1:57–65, 1983.
101:928–937, 2009. 275. Knobel H, Havard Loge J, Lund MB, et al: Late medical complications and fatigue in
260. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, Hodgkin’s disease survivors. J Clin Oncol 19:3226–3233, 2001.
and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation 276. Carver JR, Shapiro CL, Ng A, et al: American Society of Clinical Oncology clinical
therapy. JAMA 290:2831–2837, 2003. evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary
261. Chapman RM, Sutcliffe SB, Rees LH, et al: Cyclical combination chemotherapy and late effects. J Clin Oncol 25:3991–4008, 2007.
gonadal function. Retrospective study in males. Lancet 1:285–289, 1979. 277. Hodgson DC, Koh ES, Tran TH, et al: Individualized estimates of second cancer risks
262. da Cunha MF, Meistrich ML, Fuller LM, et al: Recovery of spermatogenesis after treatment for after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586,
Hodgkin’s disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 2:571–577, 1984. 2007.
263. Chapman RM, Sutcliffe SB, Malpas JS: Cytotoxic-induced ovarian failure in women 278. Engert A, Plutschow A, Eich HT, et al: Reduced treatment intensity in patients with
with Hodgkin’s disease. I. Hormone function. JAMA 242:1877–1881, 1979. early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652, 2010.

Kaushansky_chapter 97_p1603-1624.indd 1623 9/18/15 11:12 PM